Alto Neuroscience (NYSE:ANRO) Posts Earnings Results

Alto Neuroscience (NYSE:ANRO) released its earnings results on Tuesday. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.05, Zacks reports.

Alto Neuroscience Trading Down 1.3 %

Shares of ANRO stock traded down $0.06 on Thursday, reaching $4.47. The stock had a trading volume of 163,351 shares, compared to its average volume of 373,630. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.85 and a current ratio of 19.85. Alto Neuroscience has a 1 year low of $3.61 and a 1 year high of $24.00. The company has a 50 day simple moving average of $10.02 and a 200 day simple moving average of $11.46.

Analysts Set New Price Targets

ANRO has been the subject of a number of recent research reports. RODMAN&RENSHAW cut Alto Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. William Blair reiterated an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Robert W. Baird decreased their target price on shares of Alto Neuroscience from $32.00 to $10.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Rodman & Renshaw cut shares of Alto Neuroscience from a “buy” rating to a “neutral” rating in a report on Wednesday, October 23rd. Finally, Stifel Nicolaus decreased their price objective on shares of Alto Neuroscience from $32.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $20.00.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.